Bioxome

Bioxome is an exosome-based therapeutic platform developed by Orgenesis, specifically designed to address chronic kidney disease (CKD), liver diseases, and various dermatological conditions. The therapy utilizes extracellular vesicles (EVs) to deliver bioactive molecules, including regenerative and immunomodulatory factors, directly to damaged or diseased tissues. In the context of kidney disease, Bioxome aims to leverage the natural signaling and transport capabilities of exosomes to facilitate tissue repair, reduce inflammation, and potentially slow the progression of renal decline. The program is currently in the IND-enabling phase of development, focusing on establishing the safety and efficacy profiles required for clinical trial initiation.

Brand names

Bioxome

Other names

Extracellular vesicle therapyExosome therapyOrgenesis EV therapy